Please assess the completion status of the following clinical trial:

Trial Title: FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~1. ECOG Performance Status ≤ 1~2. Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401 single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II, Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF401 in combination with PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment~Exclusion Criteria:~1. Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR inhibitor.~2. Symptomatic CNS metastases which are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.~3. Patient having out of range laboratory values defined as:~   * Hematology Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L) Platelet count \< 75000/mm3 Absolute neutrophil count (ANC) \< 1500/mm3~  * Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT \> 3 x ULN Serum creatinine \> 1.5 x ULN and/or creatinine clearance ≤ 45 mL/min~  * Coagulation: PT \> 4 seconds more than ULN or INR \> 1.7~4. Pregnant or nursing (lactating) women.~Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: FGF401 50 mg fasted (Type: EXPERIMENTAL): Participants received single agent FGF401 50 mg while fasted
- Phase I: FGF401 80 mg fasted (Type: EXPERIMENTAL): Participants received single agent FGF401 80 mg while fasted
- Phase I: FGF401 80 mg fed (Type: EXPERIMENTAL): Participants received single agent FGF401 80 mg while fed
- Phase I: FGF401 120 mg fasted (Type: EXPERIMENTAL): Participants received single agent FGF401 120 mg while fasted
- Phase I: FGF401 120 mg fed (Type: EXPERIMENTAL): Participants received single agent FGF401 120 mg while fed
- Phase I: FGF401 150 mg fasted (Type: EXPERIMENTAL): Participants received single agent FGF401 150 mg while fasted
- Phase I: FGF401 80 mg + PDR001 300 mg (Type: EXPERIMENTAL): Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
- Phase I: FGF401 120 mg + PDR001 300 mg (Type: EXPERIMENTAL): Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
- Phase II: Group 1 - FGF401 120 mg QD (Type: EXPERIMENTAL): Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
- Phase II: Group 2 - FGF401 120 mg QD (Type: EXPERIMENTAL): Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
- Phase II: Group 3 - FGF401 120 mg QD (Type: EXPERIMENTAL): Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted

Based on this trial design, predict the completion outcome and termination type (if applicable).